Skip to main content
Premium Trial:

Request an Annual Quote

Theralink Partners With George Mason, Rutgers Cancer Institute on Breast Cancer Test

NEW YORK — Theralink Technologies said on Monday that it is working with George Mason University and the Rutgers Cancer Institute of New Jersey to commercialize an assay that can guide treatment of HER2 positive breast cancer patients.

The institutes recently received the US Army's Breast Cancer Research Program Breakthrough Award, worth $1.3 million, to clinically validate a test developed at George Mason that measures HER2 activation (phosphorylation) in a breast cancer biopsy to help determine if a patient will respond to treatment.

During the first year of the project, George Mason and Rutgers Cancer Institute scientists will measure HER2 activation retrospectively on previously collected pretreatment breast cancer specimens and cross reference it with treatment outcomes. The findings will then be used to design prospective clinical trials and personalize treatment options for HER2 positive patients at the Rutgers Cancer Institute and RWJBarnabas Health.

Pending a positive outcome of the work, George Mason and the Rutgers Cancer Institute have signed on Theralink to commercialize the assay using its reverse phase protein array technology, as well as to assist with the test's expanded clinical assessment to help with its adoption by oncologists.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.